Oral surgery, oral medicine, oral pathology and oral radiology · 2025
Cross-sectional analysis of fibrosis-related gene expression in drug-induced gingival enlargement associated with periodontitis.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kuo Jer-Haur, Lin Li-Wen
Аннотация
OBJECTIVE: The objective of this study was to characterize the expression patterns of inflammation- and fibrosis-related genes in drug-induced gingival enlargement (DIGE) among patients with periodontitis.
STUDY DESIGN: Gingival tissue samples from 44 patients were categorized into 4 groups: N (healthy controls), P (periodontitis), A (patients with periodontitis receiving amlodipine and valsartan without DIGE), and G (periodontitis patients with DIGE). All specimens were obtained during periodontal flap surgery at least 6 months following initial therapy. Histomorphometric analysis, immunohistochemistry, and immunofluorescence staining were used to assess protein expression levels.
RESULTS: Following initial therapy, no patient exhibited DIGE scores of 2 or 3. The expression levels of inflammation- and fibrosis-related markers, including cluster of differentiation 68, matrix metalloproteinase 12, a disintegrin and metalloproteinase 17, connective tissue growth factor, and cathepsin L, were elevated in group G compared with the other groups. Notably, group A demonstrated the highest expression of sirtuin 1 (SIRT1).
CONCLUSIONS: Effective supragingival and subgingival plaque control remains essential for managing DIGE in patients with periodontitis. The observed upregulation of SIRT1 in non-DIGE cases might indicate a potential antifibrotic role for this molecule.
STUDY DESIGN: Gingival tissue samples from 44 patients were categorized into 4 groups: N (healthy controls), P (periodontitis), A (patients with periodontitis receiving amlodipine and valsartan without DIGE), and G (periodontitis patients with DIGE). All specimens were obtained during periodontal flap surgery at least 6 months following initial therapy. Histomorphometric analysis, immunohistochemistry, and immunofluorescence staining were used to assess protein expression levels.
RESULTS: Following initial therapy, no patient exhibited DIGE scores of 2 or 3. The expression levels of inflammation- and fibrosis-related markers, including cluster of differentiation 68, matrix metalloproteinase 12, a disintegrin and metalloproteinase 17, connective tissue growth factor, and cathepsin L, were elevated in group G compared with the other groups. Notably, group A demonstrated the highest expression of sirtuin 1 (SIRT1).
CONCLUSIONS: Effective supragingival and subgingival plaque control remains essential for managing DIGE in patients with periodontitis. The observed upregulation of SIRT1 in non-DIGE cases might indicate a potential antifibrotic role for this molecule.